{"downloaded": true, "htmlmade": false, "full": {"id": "30282672", "source": "MED", "pmid": "30282672", "pmcid": "PMC6512340", "fullTextIdList": {"fullTextId": "PMC6512340"}, "doi": "10.1158/2326-6066.cir-18-0062", "title": "PD-L1 Mediates Dysfunction in Activated PD-1<sup>+</sup> NK Cells in Head and Neck Cancer Patients.", "authorString": "Concha-Benavente F, Kansy B, Moskovitz J, Moy J, Chandran U, Ferris RL.", "authorList": {"author": [{"fullName": "Concha-Benavente F", "firstName": "Fernando", "lastName": "Concha-Benavente", "initials": "F", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania."}, {"affiliation": "University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania."}]}}, {"fullName": "Kansy B", "firstName": "Benjamin", "lastName": "Kansy", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany."}}}, {"fullName": "Moskovitz J", "firstName": "Jessica", "lastName": "Moskovitz", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania."}}}, {"fullName": "Moy J", "firstName": "Jennifer", "lastName": "Moy", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania."}}}, {"fullName": "Chandran U", "firstName": "Uma", "lastName": "Chandran", "initials": "U", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Biomedical informatics, University of Pittsburgh, Pennsylvania."}}}, {"fullName": "Ferris RL", "firstName": "Robert L", "lastName": "Ferris", "initials": "RL", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania. ferrisrl@upmc.edu."}, {"affiliation": "University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania."}, {"affiliation": "Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania."}]}}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "12", "volume": "6", "journalIssueId": "2756281", "dateOfPublication": "2018 Dec", "monthOfPublication": "12", "yearOfPublication": "2018", "printPublicationDate": "2018-12-01", "journal": {"title": "Cancer immunology research", "ISOAbbreviation": "Cancer Immunol Res", "medlineAbbreviation": "Cancer Immunol Res", "NLMid": "101614637", "ISSN": "2326-6066", "ESSN": "2326-6074"}}, "pubYear": "2018", "pageInfo": "1548-1560", "abstractText": "Inhibitory immune-checkpoint receptors (ICRs), including programmed death 1 (PD-1), have been characterized as exhaustion markers on T cells that infiltrate the tumor microenvironment (TME) of many cancer types, including head and neck cancer (HNC). However, expression and function of ICRs, including PD-1, on natural killer (NK) cells remains less defined. NK cells are innate immune effector cells that lyse epidermal growth factor receptor-overexpressing HNC cells via cetuximab-mediated antibody-dependent cytotoxicity. Cetuximab is clinically effective but only in 10% to 15% of patients. Therefore, it is necessary to investigate how immunomodulation with cetuximab or PD-1 blockade might enhance NK cell responses in the TME and improve monoclonal antibody therapeutic efficacy. We observed that expression of PD-1 on NK cells marks an activated phenotype, which was suppressed only after binding programmed death ligand-1 (PD-L1). HNC patients who exhibit higher circulating PD-1<sup>+</sup> NK cells associate with better clinical outcome, and these cells are enriched in the TME. Cetuximab-mediated NK cell activation increased PD-1 expression on NK cells <i>in vitro,</i> which was confirmed <i>in vivo</i> in a prospective neoadjuvant cetuximab trial. In contrast, PD-L1 ligation of PD-1<sup>+</sup> NK cells diminished their activation status, whereas PD-1 blockade increased cetuximab-mediated NK cell activation and cytotoxicity, but only against HNC targets with high PD-L1 expression. Therefore, blocking the PD-1-PD-L1 axis may be a useful strategy to reverse immune evasion of HNC tumors with high PD-L1 expression during cetuximab therapy by reversing NK cell dysfunction.", "affiliation": "Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase II", "Controlled Clinical Trial", "research-article", "Journal Article", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": [{"grantId": "P50 CA097190", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "R01 CA110249", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "T32 CA060397", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "R01 DE019727", "agency": "NIDCR NIH HHS", "acronym": "DE", "orderIn": "0"}, {"grantId": "P30 CA047904", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Killer Cells, Natural", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}, {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Lymphocytes, Tumor-Infiltrating", "meshQualifierList": {"meshQualifier": [{"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Head and Neck Neoplasms", "meshQualifierList": {"meshQualifier": [{"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "Y"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Treatment Outcome"}, {"majorTopic_YN": "N", "descriptorName": "Survival Rate"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Aged, 80 and over"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Interferon-gamma", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Natural Cytotoxicity Triggering Receptor 1", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Programmed Cell Death 1 Receptor", "meshQualifierList": {"meshQualifier": [{"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Cetuximab", "meshQualifierList": {"meshQualifier": {"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Agents, Immunological", "meshQualifierList": {"meshQualifier": {"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "B7-H1 Antigen", "meshQualifierList": {"meshQualifier": [{"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}]}, "chemicalList": {"chemical": [{"name": "NCR1 protein, human", "registryNumber": "0"}, {"name": "CD274 protein, human", "registryNumber": "0"}, {"name": "Interferon-gamma", "registryNumber": "82115-62-6"}, {"name": "Natural Cytotoxicity Triggering Receptor 1", "registryNumber": "0"}, {"name": "Programmed Cell Death 1 Receptor", "registryNumber": "0"}, {"name": "PDCD1 protein, human", "registryNumber": "0"}, {"name": "cetuximab", "registryNumber": "PQX0D8J21J"}, {"name": "B7-H1 Antigen", "registryNumber": "0"}, {"name": "Antineoplastic Agents, Immunological", "registryNumber": "0"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1158/2326-6066.CIR-18-0062"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6512340"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6512340?pdf=render"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1158/2326-6066.cir-18-0062"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "33", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "Y", "epmcAuthMan": "N", "nihAuthMan": "Y", "manuscriptId": "NIHMS1020250", "hasTMAccessionNumbers": "N", "dateOfCompletion": "2019-09-25", "dateOfCreation": "2018-10-05", "firstIndexDate": "2018-10-05", "fullTextReceivedDate": "2020-10-21", "dateOfRevision": "2020-03-09", "electronicPublicationDate": "2018-10-03", "firstPublicationDate": "2018-10-03", "embargoDate": "2019-12-01"}, "abstract": "Inhibitory immune-checkpoint receptors (ICRs), including programmed death 1 (PD-1), have been characterized as exhaustion markers on T cells that infiltrate the tumor microenvironment (TME) of many cancer types, including head and neck cancer (HNC). However, expression and function of ICRs, including PD-1, on natural killer (NK) cells remains less defined. NK cells are innate immune effector cells that lyse epidermal growth factor receptor-overexpressing HNC cells via cetuximab-mediated antibody-dependent cytotoxicity. Cetuximab is clinically effective but only in 10% to 15% of patients. Therefore, it is necessary to investigate how immunomodulation with cetuximab or PD-1 blockade might enhance NK cell responses in the TME and improve monoclonal antibody therapeutic efficacy. We observed that expression of PD-1 on NK cells marks an activated phenotype, which was suppressed only after binding programmed death ligand-1 (PD-L1). HNC patients who exhibit higher circulating PD-1<sup>+</sup> NK cells associate with better clinical outcome, and these cells are enriched in the TME. Cetuximab-mediated NK cell activation increased PD-1 expression on NK cells <i>in vitro,</i> which was confirmed <i>in vivo</i> in a prospective neoadjuvant cetuximab trial. In contrast, PD-L1 ligation of PD-1<sup>+</sup> NK cells diminished their activation status, whereas PD-1 blockade increased cetuximab-mediated NK cell activation and cytotoxicity, but only against HNC targets with high PD-L1 expression. Therefore, blocking the PD-1-PD-L1 axis may be a useful strategy to reverse immune evasion of HNC tumors with high PD-L1 expression during cetuximab therapy by reversing NK cell dysfunction.", "journaltitle": "Cancer immunology research", "authorinfo": ["Concha-Benavente F", "Kansy B", "Moskovitz J", "Moy J", "Chandran U", "Ferris RL"], "title": "PD-L1 Mediates Dysfunction in Activated PD-1<sup>+</sup> NK Cells in Head and Neck Cancer Patients."}